Biotech entity
Of the tracked stories, 2 of 3 also mention Ziihera (zanidatamab-hrii), the most common co-covered peer. Source depth averages 2 original sources per story, versus 3.4 across the same-window beat baseline. Across a 199-day span, the pace is roughly 0.1 stories per week.
Last mentioned: Sep 24, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 3 also mention Ziihera (zanidatamab-hrii), the most common co-covered peer. Source depth averages 2 original sources per story, versus 3.4 across the same-window beat baseline. Across a 199-day span, the pace is roughly 0.1 stories per week. The clearest coverage concentration is acquisition: 1 of 3 stories, with the rest divided among 2 other categories. At 6, the average consequence score sits below the same-window beat average of 6.1. Jazz Pharmaceuticals appears in 3 tracked Biotech stories published from March 10, 2026 through September 24, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 598 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Jazz Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Anticipated Regulatory Milestones
Potential for further regulatory filings based on ongoing Phase 3 data.
Investor conference call
Zymeworks to host a conference call at 8:30 am ET to discuss final transaction details of the Theravance acquisition.
Acquisition completed
Zymeworks Inc. completes the acquisition of Theravance Biopharma, making Theravance part of Zymeworks.
AACR Annual Meeting
Expected dates for the 2026 AACR meeting where Ziihera data will be showcased.
Presentation Announcement
Zymeworks announces multiple abstracts accepted for AACR 2026.
Zymeworks completed its acquisition of Theravance Biopharma on September 23, 2026, a move that deepens its asset and royalty aggregation strategy. The combined entity adds YUPELRI to a portfolio that already spans Ziihera and pasritamig, with final deal terms set for an investor call on September 28.
Source: finanznachrichten.de · manilatimes.net
Zymeworks Inc. (ZYME) has announced multiple upcoming presentations for its lead asset, Ziihera (zanidatamab-hrii), at the 2026 AACR Annual Meeting. These presentations are expected to showcase the therapeutic's efficacy and safety across various HER2-expressing cancers, reinforcing its position in the competitive oncology landscape.
Emerging research indicates that specific non-psychoactive cannabis compounds, particularly THCV, may reverse Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). This breakthrough offers a potential pharmaceutical path for a condition that currently affects nearly 33% of the global adult population.
Jazz Pharmaceuticals is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
